FDA approves new form of Latanoprost (Xelpros) for Glaucoma
XelprosTM (latanoprost ophthalmic emulsion 0.005%) has gained FDA approval for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension.

The recommended dosage of XELPROSTM is one drop in the affected eye(s) once daily in the evening. The reduction of IOP commences approximately 3 to 4 hours after administration and the maximum effect is reached after 8 to 12 hours that lasts for at least 24 hours.

XELPROSTM is the only FDA-approved BAK-free version of Latanoprost. It joins three other FDA-approved topical glaucoma medications completely free of preservatives: Zioptan (tafluprost ophthalmic solution 0.0015%), Cosopt PF (dorzolamide-timolol ophthalmic solution 2%/0.5%), and Timoptic in Ocudose (timolol maleate ophthalmic solution 0.25% and 0.5%).

Because they are preservative free, these medications are known to be better tolerated than their BAK-preserved counterparts, which in effect, results to better adherence to treatment.

Read more here: http://new-glaucoma-treatments.com/fda-approves-preservative-free-xelpros-for-open-angle-glaucoma/
Like
Comment
Share